We are pleased to announce the publication of the first peer-reviewed clinical data on the allay™ Hydrogel Cap in Plastic and Reconstructive Surgery, Global Open. This paper, titled “”A Novel Hydrogel for Treatment and Prevention of Symptomatic Neuroma: Early Clinical Experience,” is an important step forward in building evidence-based solutions that improve care for patients undergoing peripheral nerve surgery. Importantly, these findings replicate the safety and efficacy demonstrated in preclinical studies and reported in early clinical experience. 

LOS GATOS, Calif., Oct. 7, 2025 /PRNewswire/ — Tulavi Therapeutics, a private medical technology company focused on advancing surgical solutions that address critical unmet needs in peripheral nerve surgery, today announced an expanded indication for the allay™ Hydrogel Cap. The new indication broadens access to patients weighing 25 kilograms (55 lbs) and above, extending the reach of allay™ Hydrogel Cap to include smaller patients who may be at risk of symptomatic neuromas due to trauma or amputation. “Surgeons now have a trusted solution for nerve protection and reducing the risk of symptomatic neuroma formation in patients as small as 25 kg,” said Josh Vose MD, CEO of Tulavi Therapeutics. “We are proud

LOS GATOS, Calif., Aug. 26, 2025 /PRNewswire/ — Tulavi Therapuetics has been selected to exhibit the allay™ Hydrogel Cap, a first of-its-kind surgical device designed to protect transected nerves and reduce the risk of neuroma formation, at the Vizient® Innovative Technology Exchange. Vizient, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange Sept. 17 in Las Vegas. The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s hospital clients and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to healthcare delivery or

LOS GATOS, Calif., July 23, 2025 /PRNewswire/ — Tulavi Therapeutics, a private medical technology company focused on advancing surgical solutions that address critical unmet needs in peripheral nerve surgery and repair, today announced a new partnership with Veterans Healthcare Supply Solutions (VHSS) to distribute the allay™ Hydrogel Cap to U.S. Department of Veterans Affairs (VA) hospitals and Military Treatment Facilities nationwide. This milestone brings Tulavi’s innovative technology to the forefront of veteran care and expands access to a new treatment for peripheral nerve injuries while broadening the scope of advanced surgical options for nerve protection and recovery. More than 60,000 U.S. veterans are living with limb loss, and countless others have sustained traumatic peripheral nerve injuries

Veteran medtech executive brings proven track record of scaling innovative medical device companies and successful exits LOS GATOS, Calif., June 18, 2025 /PRNewswire/ — Tulavi Therapeutics, Inc. (“Tulavi”), a medical device company transforming peripheral nerve surgery with its Adaptive Hydrogel Technology, today announced the appointment of Raymond W. Cohen to serve as Vice Chairman of its Board of Directors. “We are thrilled to welcome Ray to our Board of Directors at this pivotal moment in Tulavi’s growth trajectory,” said Josh Vose MD, CEO of Tulavi Therapeutics. “Ray brings to our board an exceptional track record of building and scaling innovative medical device companies, combined with his deep understanding of hydrogels, neurology, and device markets.